Monoclonal antibodies targeting integrins are emerging as new treatment option in inflammatory bowel diseases. Integrins are molecules involved in cell adhesion and signalling. After the successful introduction of anti-α4β7, currently anti-β7 is under evaluation in a phase three trial. Anti-β7 blocks both α4β7/MAdCAM-1 and αEβ7/E-cadherin interaction, targeting both the homing to and the retention in the gut of potential pathological T cells. Since the physiological and potential pathological roles of immune cells expressing αEβ7 are less distinct than of those expressing α4β7, an overview of the current state of knowledge on αEβ7 in mice and humans in both health and inflammatory bowel diseases is presented here, also addressing the potential consequences of anti-β7 treatment.
Introduction
Anti-integrin therapy targeting T cell trafficking to the gut is evolving for patients with inflammatory bowel diseases [IBD] 1 Integrins are transmembrane molecules that mediate cell to cell and cell to extracellular matrix interactions. They are obligate heterodimers composed of an α and β subunit, each penetrating the plasma membrane. Subunit β7 can form a heterodimeric integrin with α4 [α4β7], which can bind to mucosal addressin cell adhesion moleclule-1 [MAdCAM-1] expressed on gut endothelial cells [ Figure 1 ]. α4β7 can also bind vascular cell adhesion molecule-1 and the extracellular matrix protein fibronectin. 2 Subunit β7 can also form a heterodimeric integrin with αE [CD103] to form αEβ7. In turn, αE can only form a heterodimeric integrin with β7. For clarity, here we refer to CD103 expression when a monoclonal antibody [mAb] recognizes the αE subunit on the cell surface [by flow cytometric or immunohistochemical analysis]. Since the expression of integrins on the cell surface is constrained to the amount of α subunits inside the cell [as there is an excess of β subunits in the cell], and free subunits are not found on the cell surface, CD103 expression represents αEβ7 expression. 3 The only known ligand for αEβ7 is E-cadherin, an adhesion molecule on epithelial cells that is not found on endothelial cells. 4 αEβ7 expression on T lymphocytes is thought to contribute to their retention within the gut, whereas α4β7 is proposed as the major gut homing receptor on circulating lymphocytes. Anti-α4β7 blocks the gut-specific α4β7/MAdCAM-1 interaction and it has been approved for the treatment of moderate to severe ulcerative colitis [UC] and Crohn's disease [CD] . The mechanism of action of anti-β7 is aiming to block the binding of α4β7 and αEβ7 to MAdCAM-1 and E-cadherin, respectively, rather than depleting the β7-expressing cells. Anti-β7 is mechanistically expected to have a broader, and potentially stronger, effect than anti-α4β7, given the dual approach mechanism of action. 5 By intervening with the α4β7/MAdCAM-1 interaction, the anti-β7 should block the homing of α4β7 + lymphocytes to the gut, whereas blocking the αEβ7/E-cadherin interaction should disrupt the retention of αEβ7 + lymphocytes inside the gut epithelium. However, since αEβ7 is also expressed on other immune cells and not exclusively in the gut [see below], anti-β7 treatment may have implications beyond T lymphocyte blockade. Here we present an overview of the current knowledge on αEβ7 expression and blockade in health and IBD.
Human β7 expressing immune cells
Immune cells expressing α4β7 can be found in the gastrointestinal tract [oesophagus, stomach, small intestine, colon], and also in the cervix, prostate, urinary bladder, salivary glands, tonsils, thymus, lymph nodes, spleen and peripheral blood. 6 α4β7 is expressed on B and T lymphocytes [more abundantly on CD4 + than on CD8
+ cells], natural killer cells, basophils and eosinophils, and also on innate lymphoid cells and bone marrow precursors required for the induction of tolerogenic gut-associated dendritic cells [DCs].
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The proportion of CD4 + T lymphocytes in healthy human blood coexpressing CD45RO [memory phenotype] and α4β7 was shown to be 36%. 12 By blocking α4β7, one could expect a reduced recruitment of T lymphocytes into the intestine, given its high specificity for gut homing. However, it would also effect other immune subsets expressing α4β7 [as discussed in 13, 14 ]. After anti-α4β7 treatment in IBD patients, saturation of peripheral CD45RO + CD4 + α4β7 + T lymphocytes was 90-95%. 15, 16 There were no data presented on the examination of other cell subsets expressing α4β7 or of T lymphocyte subsets in biopsy specimens. 15, 16 Effects of anti-β7 treatment on T lymphocytes are discussed below. B cells were shown to accumulate in the periphery after β7 blockade [absolute numbers], but neither intestinal effects nor effects on other α4β7 + immune subsets were examined. 17 Diverse immune cell subsets can induce CD103 [and therefore αEβ7] expression on their surface. These cells can be found in the spleen, thymus, skeletal muscle, heart, liver, kidney, skin, brain, gastrointestinal tract, urogenital tract and lungs. [18] [19] [20] [21] [22] [23] [24] [25] 32 In addition, a regulatory alloantigen-induced CD8 + CD103 + T cell subset has been described in humans. 34 Furthermore, intestinal epithelial cells were shown to induce suppressive CD8 + CD103
+ cells, 33 suggestive of a regulatory CD103 + subset in the intestinal mucosa. 33, 34 The same research group underlined the relevance of these cells in maintaining mucosal tolerance, when they demonstrated the absence of this CD8 + regulatory activity in both UC and CD. 35 Next to migratory subsets of T lymphocytes [central memory and effector memory] expressing α4β7 to grant them access to the gut, it has become clear that another, non-migratory, subset of T lymphocytes exists: tissue-resident memory T cells [T RM ]. 36 These T RM cells reside in epithelial barrier tissues and deliver a prompt response to previously encountered pathogens, independent of recruitment of migratory T cells from the blood. Therefore, T RM mediate the rapid protective immunity to infectious agents, which is a hallmark of adaptive immune memory. Migratory T cells can, when necessary, replenish the T RM compartment. CD103 has been described on a subset of T RM factor-β [TGF-β] 30, 38, 39 [ Figure 1 ]. By blocking CD103, one could expect a reduced retention of T lymphocytes within the intestine, in particular the CD8 + subset, but also the T RM and Treg subpopulation. However, the role and function of CD103 positivity of T cells, including T RM and Treg, in chronic inflammation have not yet been elucidated. Effects of specific α4β7 and αEβ7 blockade on the migration and retention of different cell subsets would therefore be an interesting topic of investigation. Furthermore, since αEβ7 is not as gut-specific as α4β7, retention of αEβ7-expressing cells in other barrier tissues such as the lung and skin would also be affected. Even though the implications of β7 blockade for other organs are still unclear, this might lead to unwanted side effects of anti-β7 treatment in IBD patients.
Regional differences in β7 expression along the intestine
Intestinal disease location differs greatly between different clinical phenotypes of UC and CD. Therefore, potential differences in the number of CD103-expressing immune cells in different bowel segments are relevant, and should be addressed when considering anti-β7 treatment [see Figure 2] 41 These findings are in line with another study describing a linear decrease of the number of cells expressing CD103 from ascending colon to rectum in healthy humans, which was contrary to what the authors expected. 42 Therefore, a direct relation between the number of CD103 + cells and the disease distribution in UC [increasing severity from distal to proximal colon] seems unlikely. Moreover, β7 blockade might show less effect in patients with disease limited to the rectum [proctitis] compared with involvement of the entire colon [pancolitis] .
In contrast with the decreasing presence of CD103 + T lymphocytes along the intestine, a reversed presence of CD103-expressing DCs was recently reported in humans, with lower proportions of CD103 + DCs in the proximal compared with distal colon. 43 These authors also showed that healthy human colonic CD103 + DCs coexpress β7. 43 In healthy human ileum, α4 was expressed on 32% of IELs and 35% of LPLs whilst in left colon it was expressed on 48% of IELs and 58% of LPLs. 41 In another study, the proportion colonic T lymphocytes in healthy humans expressing α4β7 was 72%. 12 It remains to be determined how different β7 + immune cell subsets are distributed along the intestine, but it would be important to assess their location and function profile in order to fully understand the consequences of their blockade. specific subsets of DCs were identified, with different capacity for peripheral Treg induction. 46 Both subsets of DCs [CD103 + and CD103 -] induced expression of the gut homing integrin α4β7 on CD4 + T cells, but only CD103 + DCs were able to induce expression of C-C chemokine receptor 9 [CCR-9] on T cells. 47 CCR-9 is a homing marker for the small bowel, as it binds to C-C motif ligand 25 on epithelial cells of the small intestine. Further investigation showed only CD103 -DCs to be able to induce effector T lymphocytes that secreted proinflammatory cytokines (interleukin-6 and tumour necrosis factor-α [TNF-α]), whereas CD103 + DCs were responsible for inducing functionally suppressive FoxP3 + Tregs. 44 In mice, CD103 expression on DCs was found to be mandatory for the induction of Tregs that suppressed colitis and attenuated ileitis. 47, 48 The presence of a tolerogenic CD103 + DC population able to drive Treg development was also identified in the human gut. 29 The literature regarding effects of DCs in CD103 knockout mice is discussed below. Lack of β7 expression in the innate immune compartment resulted in accelerated T cell-mediated colitis in β7
Dendritic cells expressing CD103
-/-mice, correlating with lower numbers of retinoic acid-producing DCs. 9 Furthermore, lack of β7 + DCs impaired induction of Foxp3 + and IL-10-producing Tregs. 9 In a T cell-mediated model of colitis, a subset of CD103 -DCs accumulating in the inflamed intestine were shown to express E-cadherin and to produce colitogenic cytokines upon activation. 49 After Fms-related tyrosine kinase 3 ligand administration, this DC subset decreased in the lamina propria whereas CD103 + DCs increased, resulting in the induction of CD4 + CD25 + FoxP3 + Tregs and attenuation of murine ileitis. 48 We hypothesize that the decrease of pro-inflammatory CD103 -E-cadherin + DCs might be mediated by regulatory interaction of CD103 [DCs and Tregs] with E-cadherin, resulting in immune suppression.
Of note, Foxp3 is known to be a specific marker for functionally suppressive CD4 + Tregs in mice. 50 The role of this marker for Tregs in humans remains controversial, as activation of non-Tregs can lead to transient Foxp3 expression without inducing a suppressive function. 51 This does not concern the interpretation of the data presented here, as it mostly regards Tregs in mice, but caution should be taken when interpreting human data on this subject.
A dramatic loss of CD103 + intestinal DCs was observed during experimental colitis [CD4 + CD62L
+ transfer model and chronic dextran sulphate sodium colitis] in the lamina propria and mesenteric lymph nodes [MLN] compared with healthy mice. 52 Recently, this was reaffirmed in dextran sulphate sodium colitis mice, with decreased frequencies of CD103 + DC subsets associated with a reduced ability to promote Treg generation. 53 CD103 + DCs with similar phenotype and functions as in mice were also found in human MLN. 30, 44 Reduced numbers of CD103 + DCs were also described in the colonic biopsy specimen of patients with active UC compared with healthy controls. 54 Similarly, statistically significant lower numbers of CD103 + DCs were reported in inflamed compared with noninflamed gut mucosa of CD patients. 55 The CD103 + DC population increased statistically significantly after anti-TNF-α treatment. 55 Taken together, these findings support a role for CD103 + DCs in the intestinal maintenance of immune homeostasis, as they are involved in Tregs induction in the gut. Therefore, blocking β7 would not exclusively block αEβ7 + on T lymphocytes, but might also affect the CD103 + subset of DCs and β7 + innate immune cells, thereby exercising a potentially negative influence on long-term immune homeostasis.
The process of Tregs induction by CD103 + DCs is dependent on TGF-β and potentiated by vitamin A metabolite retinoic acid. On the other hand, TGF-β can also induce formation of Th-17 cells in the presence of the pro-inflammatory cytokine IL-6 56 [see Figure 3 ]. Furthermore, as described earlier, TGF-β induces CD103 expression on both CD4 + and CD8 + T lymphocytes. 30, 38, 39 TGF-β signalling is regulated through the SMAD-pathway. Overexpression of SMAD7 in transgenic mice completely impaired the TGF-β mediated up-regulation of CD103 expression on CD4 + T cells and reduced the number of intestinal IEL in these mice by 46%, compared with their wild-type littermates. 57 To our knowledge, this has not yet been studied in humans. However, overexpression of SMAD7 was reported in the inflamed intestine of IBD patients, concomitant with abnormally decreased TGF-β1 activity. 58 An oral antisense therapy inhibiting SMAD7 was remarkably effective in inducing remission and clinical response in a phase two trial in CD patients. 59 It is tempting to speculate that the inhibition of SMAD7 could ensure an increased functional TGF-β activity and might result in up-regulation of CD103 expression on T lymphocytes. 57,60
CD103 and E-cadherin expression in IBD patients
A detailed overview of different papers studying CD103 expression in IBD patients can be found in Table 1 . One study examined CD103 expression on IELs and LPLs in surgical colonic resection specimen of patients with CD [disease activity and location unclear], UC [both active and inactive disease, disease location unclear] and controls [colectomy due to colorectal carcinoma]. 61 No difference in CD103 expression on IELs was observed between IBD patients and controls. Higher numbers of CD103 + LPLs were found in CD patients compared with UC patients and controls. In this study, no difference regarding E-cadherin expression was found between patients and controls. Another study was performed on CD103 expression on IEL and LPL in the ileum and colon of CD patients [active and inactive disease taken together] and healthy controls. 41 In contrast with the aforementioned study, no difference was found for CD103 expression on LPL between CD and controls. Furthermore, decreased expression of CD103 was found on IEL in the ileum of CD patients compared with controls. The only cell subset with a statistically significant overexpression of CD103 was the CD3 + CD25 + LPL of the left hemicolon, which also include Tregs. The same research group performed a pilot study in patients with CD, UC [partly under treatment with mesalazine and/or corticosteroids] and healthy controls. 62 IL-2 expanded T cells were generated from inflamed colonic biopsy specimens. After expansion, increased CD103 expression was observed on CD3 + and CD8 + cells, but not on CD4 + cells, in CD patients compared with controls. In UC patients this was only demonstrated on the CD8 + subset and not on CD4 + or overall CD3 + cells. + cells did not differ between patients and controls. Altogether, there is no strong evidence for increased CD103 expression on T cells in the gut of IBD patients. At the level of gene expression of cell adhesion molecules, no statistically significant difference was found for gene expression of αE and β7 in the [inflamed] mucosa between active IBD patients and healthy controls or post infliximab treatment. 64 Gene expression of E-cadherin in inflamed colonic samples of IBD was statistically significantly decreased compared with healthy controls. The authors seriously challenged the use of this pathway as treatment target, as they observed no up-regulation of αE or β7 in the inflamed IBD mucosa next to down-regulation of its principal ligand E-cadherin. On the other hand, support for the use of anti-α4β7 in patients with IBD was found in this study, as α4 and MAdCAM-1 gene expression was significantly increased in active inflammation and both decreased in infliximab responders after therapy.
Results on intestinal E-cadherin expression in IBD are also inconsistent, but most studies advocate a decreased expression. As mentioned, E-cadherin gene expression was down-regulated in active colonic IBD when compared with healthy controls. 64 In line with this, immunohistochemical staining of colonic specimens of IBD patients showed decreased staining of E-cadherin at the mucosal edges of ulcerations in all active UC patients and in half of active CD patients. Non-ulcerated and non-inflamed mucosa showed normal E-cadherin expression. 65 E-cadherin was downregulated in another study performed in UC patients. 66 On the other hand, E-cadherin was upregulated [immunohistochemistry and mRNA] at sites adjacent to ulcerations, with absence inside the ulceration of ileal and colonic biopsy specimens of IBD patients with active disease. 67 E-cadherin expression is likely to be adjusted to local CD103 expression. It is conceivable that decreased E-cadherin expression in gut mucosa of IBD patients might diminish the effect of anti-β7 treatment on retention of CD103 + T lymphocytes within the epithelium. Overall, the knowledge on CD103 and E-cadherin expression in IBD patients is most likely blurred by inhomogeneous patient cohorts including both active and inactive disease and under various types of anti-inflammatory treatment. Examining CD103 and E-cadherin together might provide more clarity on their expression and interaction. Furthermore, studies have only addressed CD103 expression on the total T cell population, whereas subpopulations may differ in expression levels and may also be affected differently by anti-β7 treatment. So far there is no convincing evidence of increased CD103 or β7-expression on T cell [subsets] in the inflamed gut mucosa of IBD patients.
Lessons from αEβ7in mouse models
Most of the current knowledge on αEβ7 blockade is derived from animal models. Anti-β7 treatment was shown to reduce [but not heal] colitic lesions in a CD45RB high CD4
+ T cell transfer model of murine colitis. 68 In a study on anti-β7 treatment in SCID mice after T cell transfer, mice were sacrificed 1.5 h after anti-β7 administration. 5 In this model, lower numbers of lymphocytes were found in the inflamed colon of treated mice and there was no apparent effect on the spleen. However, the observational period was too short to determine long-term effects. Conversely, another study showed that the transfer of naïve T cells from β7 knockout mice into SCID mice only delayed the development of murine colitis [symptoms started after 20 weeks instead of within 3-4 weeks] and did not alter the course of disease. 69 β7 expression was not even a strict requirement for the localization of T lymphocytes to the mouse intestine [β7 knockout mice] and it was suggested that alternative pathways might compensate a lack of β7. Another study on β7 knockout mice demonstrated less pronounced colitis compared with wild-type mice, coinciding with decreased numbers of mucosal proinflammatory monocytes. 70 Progenitors of these monocytes were shown to express β7, but expression of α4β7 and/or αEβ7 was not studied individually. Anti-β7 treatment and β7 knockout models affect α4β7-and αEβ7-expressing cells simultaneously. This impairs differentiation between the specific effects of anti-β7 treatment on homing [α4β7] or retention [αEβ7] of immune cells.
Anti-CD103 treatment was able to prevent the development of colitis and ameliorated existing colitis in a TNP-OVA-immunized IL-2 knock-out mouse model. 71 When mice were sacrificed 7 days after the first anti-CD103 injection, a reduction of CD4 + LPLs was seen, but surprisingly there was little effect on CD8 + T lymphocytes. Moreover, the treatment led to inflammation of the spleen. Another study failed to confirm any role of CD103-expressing T lymphocytes in the development of colitis and showed that accumulation of CD4 + T cells in the intestine did not require CD103-expressing T lymphocytes. 47 Colitis developed normally in the absence of CD103-expressing T lymphocytes in a T cell transfer mouse model and regulatory CD103 -T cells were still able to suppress colitis. 47 Overall, there is a broad range of effects in mice treated with anti-β7 or anti-CD103, and retention of T lymphocytes in the gut seemed to be compensated by influx of migratory T cells, in the absence of CD103 and β7.
With respect to DC subsets, similar composition was found in Rag2 -/-mice and CD103
-/-Rag2 -/-mice, but the function of these DCs was not analysed. In another study, CD103
-/-mice with a helminth infection displayed comparable frequencies of DCs to wild-type mice. 72 Unfortunately, the ability of these DCs to generate retinoic acid, Tregs and α4β7/CCR9-expressing T lymphocytes was not analysed. On the other hand, in mice with induced diabetes, anti-CD103 immunotoxin [with a depleting effect on CD103
+ cells] resulted in a dramatic loss of DCs and Tregs in the mesenteric lymph nodes. 73 Therefore, even though the number of DCs present after CD103 knockout induction in mice does not seem to differ, it is conceivable that these DCs might have a more pro-inflammatory function. Another explanation could be that DCs need β7 to exert their function of inducing suppressive Tregs or to block the function of CD103 -E-cadherin + DC subsets.
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A regulatory CD8 + CD103 + T cell subset that could inhibit CD4 + proliferation in vitro and attenuate adoptively transferred ileitis has also been described in mice. 74 This was confirmed in another study, in which it is shown that only the CD8 + CD103
+ , not the CD8 + CD103 -, T lymphocyte subset could suppress T cell mediated colitis in Rag2 -/-mice. 75 Remarkably, numbers of regulatory CD8 + CD103 + blood T lymphocytes increased gradually during a year of anti-α4 treatment in patients with multiple sclerosis, more significantly in patients with clinical response. 76 These data show evidence of a regulatory CD8 + CD103
+ T cell subset. The effects of anti-β7 treatment on these subsets have not yet been evaluated.
Anti-β7 treatment in IBD patients
The rationale behind anti-β7 treatment is based on mouse studies and some of the studies described in Table 1 , under the assumption of an up-regulated CD103 expression in the inflamed intestine of IBD patients. 41, 61, 62 The phase one trial of anti-β7 in IBD included 48 patients with UC in order to assess safety and tolerability. 77 Overall it was well tolerated, with headache as the most common adverse event. + numbers in the peripheral blood in line with the hypothesis that anti-β7 interferes with recruitment of effector T cells to the intestine. Peripheral CD8 + β7
+ frequencies remain the same. In the inflamed colonic mucosa, the β7 receptors on CD8 + T lymphocytes were maximally occupied [both αEβ7 and α4β7]. However, frequencies of these lymphocytes remained comparable to placebo-treated patients. Unfortunately, CD4 + β7
+ T lymphocytes were not analysed in the colonic biopsy specimens. Intestinal biopsy mRNA levels of αE, β1 and β7 were unchanged. Therefore, the mechanism of action of anti-β7 seems more blocking than depleting. Clinical remission at Week 10 was observed in 8/39 patients with 100 mg, 4/39 patients with 300 mg and 0/41 patients with placebo. A simultaneous endoscopic and rectal bleeding subscore of 0 at Week 10 was found in 4/39 patients with 100 mg, 3/39 with 300 mg and 0/41 with placebo. An indirect comparison, posed in the discussion of this phase two trial, of anti-β7 with the phase two trial of anti-α4β7 15 indicated a higher placebo-corrected clinical remission in patients treated with anti-β7 [21% compared with 18.5%]. However, this was an unequal comparison, since the endpoint after 6 weeks of treatment in the anti-α4β7 trial was compared with the endpoint after 10 weeks in the anti-β7 trial. The placebo-corrected clinical remission in the 100 mg anti-β7 group after 6 weeks of treatment was much lower [5%] than in the anti-α4β7 trial [18.5%] . The same trend was seen when making an indirect comparison for endoscopic remission: at Week 6, the placebo-corrected endoscopic remission was 20% in the anti-α4β7 trial as opposed to 5% in the anti-β7 trial. Of note, patient cohorts studied were different regarding disease severity and refractoriness to previous medication, and both studies allowed comedication during the study period. Obviously, final comparison can only be made in a head-to-head trial studying both mAbs.
In a recent post hoc study on the potency of biomarkers in IBD patients treated with anti-β7, gene expression of integrin alpha E [ITGAE] and granzyme A were studied as potential predictive markers of response. 78 Baseline characteristics showed lower endoscopy and histology scores in patients with ITGAE high compared with ITGAE low patients. The clinical relevance of this observation was denoted as unclear, but we wonder if the ITGAE high expression could in fact reflect a predominant anti-inflammatory pathway in these patients? Histological improvement was only found in the ITGAE low group and not in the ITGAE high group. Considering the earlier mentioned gradual decline of CD103 + T lymphocytes along the intestine, it might be possible that there are other identifiable subgroups of patients who might benefit from anti-β7 treatment [e.g. ileal disease when compared with distal colonic disease]. On the other hand, in view of αEβ7 expression on specific regulatory immune cell subsets, comprehensive evaluation of these subsets might also uncover markers to stratify patients for personalized medicine. It would be of interest to determine the actual integrin expression on the surface of all different subsets of immune cells in the gut by, for example, fluorescence-activated cell sorting [FACS] analysis before and after anti-β7 treatment.
Conclusion
Intervening in the gut-specific infiltration of T lymphocytes [α4β7 + ] is a very effective approach to directly address the site of inflammation in IBD. On the other hand, the effect of blocking retention of T lymphocytes [αEβ7 + ], which already populate the inflamed intestinal mucosa, is less clear. In addition, the effect of anti-β7 treatment on the diverse immune subsets expressing αEβ7 in the peripheral blood as well as the different epithelial compartments has not yet received sufficient attention.
We believe that, given the current knowledge, there is no evidence for an exclusively pathogenic role of αEβ7-positive intestinal immune cells in IBD, as there is no consistent evidence for increased αEβ7 expression on lymphocytes in patients. Moreover, αEβ7 integrin blockade might interfere with the action of different regulatory immune cell subsets. Conflicting results have been reported in different mouse models regarding treatment with anti-CD103 and anti-β7 mAb; therefore the results of the phase three anti-β7 trial are eagerly awaited. In the meantime, more comprehensive studies on αEβ7 expression in IBD are needed to elucidate its true nature and eventually define specific subgroups of patients that might benefit from anti-β7 treatment. Furthermore, it is essential to take into account the possible effects of αEβ7 blockade on long-term immune homeostasis, as well as side effects on other organs and the response to intestinal infections.
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